Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats
Topic overview
Preclinical study demonstrates that high-dose clodronate, a VNUT inhibitor, reduces hepatic steatosis and inflammation in a rat model of short bowel syndrome receiving total parenteral nutrition. Findings suggest potential therapeutic application for preventing intestinal-failure-associated liver disease in SBS patients.
Key takeaways
- High-dose clodronate (60 mg/kg twice weekly) reduced hepatic steatosis in rat SBS model receiving TPN compared to controls.
- Clodronate suppressed IL-6 and Nlrp3 inflammatory markers in liver tissue, suggesting anti-inflammatory mechanism in IFALD.
- VNUT inhibition may offer therapeutic approach for intestinal-failure-associated liver disease in short bowel syndrome patients.
- Effect was dose-dependent; high-dose clodronate showed histologic improvement while low-dose (20 mg/kg) did not differ from control.
- Lipid metabolism gene expression unchanged, suggesting clodronate acts via inflammation reduction rather than direct metabolic modulation.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Favorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats. GlobalCastMD Medical Library. 2024-11-13. https://dev.library.globalcastmd.com/article/9422?via_space=staycurrentmd
Comments